Development of libiguin as medicament for erectile dysfunction and premature ejaculation
|Coordinator||Dicot AB - Dicot AB c/o Uppsala Universitet Holding|
|Funding from Vinnova||SEK 300 000|
|Project duration||March 2017 - November 2017|
|Call||Innovativa startups fas 1 Våren 2017|
Purpose and goal
The purpose of the project in its entirety is to develop an industrial process for the manufacture of libiguin API to enable preclinical toxicity tests and clinical trials to finally register libiguin as a drug and ensure that the libiguin API can be manufactured in sufficient quantities for the world markets.
Expected results and effects
Phase 1 of the project included prospecting raw-materials and development of extraction and purification methods for a precursor in the synthesis of libiguin. The prospecting has been successful; sources with good availability have been identified and one ton of raw-materials have already been acquired. An extraction and purification method has been developed and 60 grams of the precursor has already been obtained.
Planned approach and implementation
Prospecting has been carried out in cooperation with consultants. Extraction and purification methods have been developed in cooperation with CRO. The project has been completed in accordance with the project plans, and much faster than originally thought. One ton raw-materials have been collected and delivered to Sweden. Overall, Vinnova´s project funds have significantly reduced the risk of the project by ensuring that we now have sufficient raw-materials for the project´s continuation.